AstraZeneca’s Phase III program of lesinurad in combination with xanthine oxidase inhibitors produced optimistic results for gout patients. If approved, this combination therapy will add a significant boost to the company’s product pipeline.
via Marketing - United States - Latest News http://ift.tt/1oK3bVb
via Marketing - United States - Latest News http://ift.tt/1oK3bVb
Keine Kommentare:
Kommentar veröffentlichen